BIO – James A. Wells, PhD

James A. Wells, PhD

James A. Wells, PhD

James A. Wells, PhD, an internationally recognized biochemist and leader in the development of new technologies for engineering proteins and for identifying small molecules to aid in drug discovery, is a member of the prestigious National Academy of Sciences. He joined UCSF in 2005 as the first holder of the Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences, and has been the chair of the Department of Pharmaceutical Chemistry in the UCSF School of Pharmacy since July 1, 2008.
Wells is a professor in his home Department of Pharmaceutical Chemistry and holds a joint appointment as professor in the UCSF School of Medicine’s Department of Cellular and Molecular Pharmacology.At UCSF, Wells’ research group focuses on the discovery and design of small molecules that trigger or modulate cellular processes in inflammation and cancer. Using small molecules and engineered proteins, the Wells lab is studying how enzymes known as proteases are turned on to cleave particular proteins in cells. The lab is focusing on one set of proteases, known as caspases, that kill virally infected or precancerous cells. These enzymes act as demolition experts and help us understand the essential protein struts that support life. Wells’ research spans the multiple disciplines of biophysics, cell biology, molecular biology, biochemistry and chemistry.

Wells also directs the Small Molecule Discovery Center (SMDC), which he founded. The SMDC is located at UCSF’s Mission Bay campus in the California Institute for Quantitative Biosciences (QB3), where Wells is a faculty affiliate. Center activities focus on helping UCSF and QB3 researchers identify small molecules that modulate biochemical or cellular processes and have the potential to alter disease states. The ultimate goal of SMDC research is to help pave the way for the development of new small molecule therapeutics.

Before joining UCSF, Wells was a founding scientist in Genentech’s Protein Engineering Department. He then founded Sunesis Pharmaceuticals, where he served as president and chief scientific officer and co-invented a novel drug discovery process, called Tethering, to efficiently screen molecules in search of the most potent compounds to block specific protein action.

In addition to his membership in the National Academy of Sciences, Wells is a recipient of many honors, including the Hans Neurath Award by the Protein Society, the Pfizer Award given by the American Chemical Society, the du Vigneaud Award given by the American Peptide Society and the 2006 Hartwell Individual Biomedical Research Award. He earned a PhD degree in biochemistry from Washington State University and completed postdoctoral work at Stanford University School of Medicine.

Download [ Audio File (10 MB)] [ Text Transcript (90 KB)]
Back to the ACS Careers Industry Forum

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: